GSA Capital Partners LLP Acquires Shares of 36,043 Pacira Biosciences Inc (NASDAQ:PCRX)

GSA Capital Partners LLP acquired a new stake in Pacira Biosciences Inc (NASDAQ:PCRX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 36,043 shares of the company’s stock, valued at approximately $1,568,000. GSA Capital Partners LLP owned approximately 0.09% of Pacira Biosciences at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Frontier Capital Management Co. LLC acquired a new stake in shares of Pacira Biosciences during the 1st quarter worth approximately $52,509,000. Stephens Investment Management Group LLC grew its position in shares of Pacira Biosciences by 0.9% during the 2nd quarter. Stephens Investment Management Group LLC now owns 1,210,605 shares of the company’s stock worth $52,649,000 after buying an additional 10,868 shares during the period. Baillie Gifford & Co. grew its position in shares of Pacira Biosciences by 6.1% during the 1st quarter. Baillie Gifford & Co. now owns 990,908 shares of the company’s stock worth $37,715,000 after buying an additional 57,367 shares during the period. Elk Creek Partners LLC grew its position in shares of Pacira Biosciences by 5.3% during the 1st quarter. Elk Creek Partners LLC now owns 564,576 shares of the company’s stock worth $21,488,000 after buying an additional 28,382 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Pacira Biosciences by 7.4% during the 4th quarter. Geode Capital Management LLC now owns 516,774 shares of the company’s stock worth $22,231,000 after buying an additional 35,635 shares during the period.

NASDAQ PCRX traded down $1.40 during trading on Friday, reaching $36.54. 563,787 shares of the stock traded hands, compared to its average volume of 626,454. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of 126.00, a price-to-earnings-growth ratio of 1.70 and a beta of 1.15. The stock’s 50-day moving average price is $41.52 and its 200 day moving average price is $41.26. The company has a quick ratio of 4.12, a current ratio of 4.75 and a debt-to-equity ratio of 0.99. Pacira Biosciences Inc has a fifty-two week low of $35.07 and a fifty-two week high of $55.00.

Pacira Biosciences (NASDAQ:PCRX) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.41 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.14 by $0.27. Pacira Biosciences had a net margin of 2.04% and a return on equity of 8.62%. The firm had revenue of $102.60 million for the quarter, compared to analyst estimates of $99.92 million. During the same quarter in the previous year, the firm posted $0.24 earnings per share. The business’s revenue was up 22.0% on a year-over-year basis. Analysts anticipate that Pacira Biosciences Inc will post 0.66 EPS for the current fiscal year.

In other Pacira Biosciences news, insider Richard Scranton sold 15,510 shares of Pacira Biosciences stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $43.21, for a total value of $670,187.10. Following the transaction, the insider now owns 23,111 shares of the company’s stock, valued at $998,626.31. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Lauren Bullaro Riker sold 967 shares of Pacira Biosciences stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $42.91, for a total transaction of $41,493.97. The disclosure for this sale can be found here. In the last ninety days, insiders sold 77,091 shares of company stock worth $3,246,975. Insiders own 5.80% of the company’s stock.

PCRX has been the subject of several analyst reports. Stifel Nicolaus set a $42.00 price target on shares of Pacira Biosciences and gave the stock a “hold” rating in a research report on Friday, August 9th. Wedbush set a $85.00 price target on shares of Pacira Biosciences and gave the stock a “buy” rating in a research report on Friday, June 28th. Mizuho upgraded shares of Pacira Biosciences from an “underperform” rating to a “neutral” rating and boosted their price objective for the company from $29.00 to $38.00 in a report on Monday, May 6th. Barclays assumed coverage on shares of Pacira Biosciences in a report on Tuesday, June 11th. They set an “overweight” rating and a $52.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Pacira Biosciences from a “sell” rating to a “hold” rating and set a $47.00 price objective for the company in a report on Friday, August 2nd. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $54.13.

Pacira Biosciences Company Profile

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Recommended Story: What does a neutral rating on stocks mean?

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Biosciences Inc (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.